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Resistant hypertension is present in patients who have a blood
pressure above target despite treatment with 3 or more drugs,
including a diuretic. Poor adherence to treatment is a major factor to
explore before making a reliable diagnosis of treatment-resistant
hypertension (TRH). Directly observed therapy and ambulatory blood
pressure monitoring are important adjuncts to this diagnosis, which is
clinically important because people with TRH have poor cardiovascular
outcomes. After combining an ACE inhibitor/ARB, calcium antagonist
and diuretic, cheap and effective next steps include additional diuretic
therapy, a mineralocorticoid antagonist, an alpha-adrenoceptor antag-
onist or beta-adrenoceptor antagonist. Currently, it is not clear which
approach offers the greatest beneﬁt. More recently, endothelin (ET)
receptor antagonists (ETRAs) have undergone clinical trials in this
indication; in particular the landmark studies with darusentan
(DORADO and DORADO-AC). Although most observers would argue
that darusentan was both safe and effective in this indication [1], the
drug failed to achieve its predetermined primary endpoint in phase 3
trials, and the drug was not take forward. Together with data from
studies with bosentan in primary hypertension, sitaxentan in hyper-
tensive chronic kidney disease, and atrasenten in diabetic nephropathy,
these agents seem not only to lower blood pressure, but also to reverse
arterial stiffness, endothelial dysfunction and renal dysfunction (in
terms of a proteinuria surrogate). On the other hand, ETRAs cause ﬂuid
retention and are teratogenic, and the balance of efﬁcacy against safety
and cost (now low for what are mostly generic drugs) remains unclear.
While there may still be a market for a new agent in TRH, drug therapy
will now have to compete with devices such as those used in renal
denervation therapy and baroreceptor stimulation therapy.
[1] Webb DJ. DORADO: opportunity postponed: lessons from studies of
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In the human body, all cells, tissues, organs, and systems operate
coherently. The presence of well- developed neurohumoral commu-
nications among these components of the body is the essential
infrastructure that makes coherent functioning possible. Since the
design goal of the cardiovascular system is to provide adequate
perfusion to peripheries, the normal operation of cardiovascular
regulator y system is vital. Recent investigations indicated that the
neurohumoral regulator y system plays a central role in the
pathogenesis of refractory cardiovascular disease such as hyperten-
sion, hypotension and heart failure. The fact that one cannot sustain
arterial pressure even for a few seconds in the upright position
without baroreﬂex indicates that pressure stabilization is an essential
requirement to maintain homeostasis. Hence the vasomotor center in
the brainstem regulates the cardiovascular systemmainly through the
autonomic nervous system, we may be able to intervene the function
of cardiovascular system nonpharmacologically if we can artiﬁcially
modulate the autonomic nerves. The case of central baroreﬂex failure
is an archetypal pathophysiology requiring such an intervention. In
treating this disease, it is conceivable that one can implement an
artiﬁcial baroreﬂex system as a kind of biological proxy capable of
emulating the native central baroreﬂex function of the failing
vasomotor center. The artiﬁcial baroreﬂex system consists of a
pressure sensor, microprocessor and nerve stimulator for activation
of sympathetic efferent nerves. The system operates as an intelligent
negative feedback regulator, and has been demonstrated early in the
2000s to be effective in restoring normal baroreﬂex functioning. The
clinical impact of direct manipulation of autonomic functions is very
profound, particularly in the treatment of refractory cardiovascular
disease. We would like to discuss the principle of closed loop
neuromodulation, implementation of the artiﬁcial regulators into the
cardiovascular systems and renal denervation as well as baroreﬂex
activation in managing refractory hypertension.
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